The world’s largest manufacturer of contrast agents for gastrointestinal radiology has taken a 5% equity position in PointDx, an emerging medical technology company focused on the development of virtual colonoscopy software and structured reporting
The world’s largest manufacturer of contrast agents for gastrointestinal radiology has taken a 5% equity position in PointDx, an emerging medical technology company focused on the development of virtual colonoscopy software and structured reporting solutions for radiology. The deal also provides E-Z-EM with a three-year warrant to purchase an additional 120,000 shares and one seat on the PointDx board of directors. By taking an equity stake in PointDx, E-Z-EM hopes to follow and support the development of new applications in GI medicine.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.